These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 37504338)

  • 1. The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study.
    Sue-Chue-Lam C; Brezden-Masley C; Sutradhar R; Yu AYX; Baxter NN
    Curr Oncol; 2023 Jul; 30(7):6508-6532. PubMed ID: 37504338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of oxaliplatin-containing adjuvant duration with post-treatment fall-related injury and fracture in patients with stage III colon cancer: a population-based retrospective cohort study.
    Sue-Chue-Lam C; Brezden-Masley C; Sutradhar R; Yu AYX; Baxter NN
    BMC Cancer; 2024 Jul; 24(1):878. PubMed ID: 39039514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
    André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
    Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
    Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
    JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
    N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
    Loree JM; Sha A; Soleimani M; Kennecke HF; Ho MY; Cheung WY; Mulder KE; Abadi S; Spratlin JL; Gill S
    Clin Colorectal Cancer; 2018 Jun; 17(2):156-163. PubMed ID: 29486916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study.
    Boyle JM; Kuryba A; Cowling TE; van der Meulen J; Fearnhead NS; Walker K; Braun MS; Aggarwal A
    Int J Cancer; 2022 Jan; 150(2):335-346. PubMed ID: 34520572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
    Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
    Yoshino T; Oki E; Misumi T; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Nakamura F; Bando H; Taniguchi H; Sakamoto Y; Shiozawa M; Nishi M; Horiuchi T; Yamagishi H; Sakamoto J; Mizushima T; Ohtsu A; Mori M
    J Clin Oncol; 2022 Oct; 40(29):3419-3429. PubMed ID: 35512259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
    Yamazaki K; Yamanaka T; Shiozawa M; Manaka D; Kotaka M; Gamoh M; Shiomi A; Makiyama A; Munemoto Y; Rikiyama T; Fukunaga M; Ueki T; Shitara K; Shinkai H; Tanida N; Oki E; Sunami E; Ohtsu A; Maehara Y; Yoshino T
    Ann Oncol; 2021 Jan; 32(1):77-84. PubMed ID: 33121997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and Prescriber Variation in the Duration of Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer From 2007 to 2019: A Population-Based Retrospective Cohort Study.
    Sue-Chue-Lam C; Brezden-Masley C; Sutradhar R; Yu AYX; Baxter NN
    Clin Colorectal Cancer; 2023 Dec; 22(4):431-441.e9. PubMed ID: 37648568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
    JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
    Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
    Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.